More tools:Markets·Screener·Research·Chat

Zevra Therapeutics, Inc. Common Stock (ZVRA) Financial Statements

Zevra Therapeutics, Inc. Common Stock
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG0026ZG1G4
XNAS · usd
12.68▲ 0.28 (2.22%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close12.40
Day's Range12.18 – 12.90
52-Week Range7.16 – 15.04
Volume1.1M
Avg Volume1.0M
Share Statistics
Shares Outstanding
Employees61
ExchangeXNAS
Listed2015-04-16
Share count as of July 31, 2026
Loading Income Statement…
Key questions about Zevra Therapeutics, Inc. Common Stock (ZVRA)
What is Zevra Therapeutics, Inc. Common Stock's Market Cap?
Zevra Therapeutics, Inc. Common Stock's Market Cap is $752.7M, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Enterprise Value?
Zevra Therapeutics, Inc. Common Stock's Enterprise Value is $607.4M, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Trailing P/E?
Zevra Therapeutics, Inc. Common Stock's Trailing P/E is 12.9×, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Price / Sales?
Zevra Therapeutics, Inc. Common Stock's Price / Sales is 5.5×, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's EV / Revenue?
Zevra Therapeutics, Inc. Common Stock's EV / Revenue is 4.5×, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's EV / EBITDA?
Zevra Therapeutics, Inc. Common Stock's EV / EBITDA is 7.0×, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Revenue (TTM)?
Zevra Therapeutics, Inc. Common Stock's Revenue (TTM) is $136.1M, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Net Income (TTM)?
Zevra Therapeutics, Inc. Common Stock's Net Income (TTM) is $58.3M, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's EBITDA?
Zevra Therapeutics, Inc. Common Stock's EBITDA is $83.9M, based on as-reported figures from SEC (XBRL) filings.
What is Zevra Therapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Zevra Therapeutics, Inc. Common Stock's Diluted EPS (TTM) is 0.98, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue, net
YoY growth+53.3%+77.5%+183.4%+605.4%
Cost of product revenue (excluding $X and $X in intangible asset amortization for the three months ended XXX XX, 20XX, and 20XX, respectively, and $X and $X in intangible asset amortization for the six months ended XXX XX, 20XX, and 20XX, respectively, shown separately below)
Intangible asset amortization
Impairment of intangible assets—
Gain on sale of future royalties, intellectual property, and other assets, net——
Operating expenses:
Research and development
Selling, general and administrative
Total operating expenses
% of revenue53.1%69.5%67.3%78.1%
Income (loss) from operations
% of revenue42.3%144.0%27.3%15.9%
Other (expense) income:
Gain on sale of PRV—
Loss on extinguishment of debt——
Loss on derivative liability——
Interest expense
Fair value adjustment related to warrant and CVR liability
Fair value adjustment related to investments
Interest and other income, net
Total other (expense) income
Income before income taxes
Income tax expense
Net income
% of revenue22.1%104.6%35.6%-2.1%
Basic (in dollars per share)
Diluted (in dollars per share)—